Protalix BioTherapeutics Inc (PLX)
1.66
-0.03
(-1.78%)
USD |
NYAM |
Nov 21, 16:00
1.65
-0.01
(-0.60%)
After-Hours: 20:00
Protalix BioTherapeutics Revenue (Quarterly): 17.96M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 17.96M |
| June 30, 2024 | 13.47M |
| March 31, 2024 | 3.748M |
| December 31, 2023 | 10.49M |
| September 30, 2023 | 10.34M |
| June 30, 2023 | 35.08M |
| March 31, 2023 | 9.588M |
| December 31, 2022 | 8.617M |
| September 30, 2022 | 14.18M |
| June 30, 2022 | 8.753M |
| March 31, 2022 | 16.08M |
| December 31, 2021 | 8.549M |
| September 30, 2021 | 12.05M |
| June 30, 2021 | 6.427M |
| March 31, 2021 | 11.32M |
| December 31, 2020 | 19.50M |
| September 30, 2020 | 10.79M |
| June 30, 2020 | 10.97M |
| March 31, 2020 | 21.65M |
| December 31, 2019 | 17.76M |
| September 30, 2019 | 14.25M |
| June 30, 2019 | 12.25M |
| March 31, 2019 | 10.44M |
| December 31, 2018 | 10.35M |
| September 30, 2018 | 12.34M |
| Date | Value |
|---|---|
| June 30, 2018 | 4.838M |
| March 31, 2018 | 6.714M |
| December 31, 2017 | 4.305M |
| September 30, 2017 | 7.526M |
| June 30, 2017 | 6.358M |
| March 31, 2017 | 2.889M |
| December 31, 2016 | 2.081M |
| September 30, 2016 | 4.67M |
| June 30, 2016 | 1.769M |
| March 31, 2016 | 0.679M |
| December 31, 2015 | |
| September 30, 2015 | 1.336M |
| June 30, 2015 | 1.336M |
| March 31, 2015 | 1.692M |
| December 31, 2014 | -10.25M |
| September 30, 2014 | 3.707M |
| June 30, 2014 | 2.686M |
| March 31, 2014 | 7.383M |
| December 31, 2013 | -10.39M |
| September 30, 2013 | 3.359M |
| June 30, 2013 | 3.064M |
| March 31, 2013 | 3.968M |
| December 31, 2012 | 0.048M |
| September 30, 2012 | 5.39M |
| June 30, 2012 | 25.26M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.748M
Minimum
Mar 2024
35.08M
Maximum
Jun 2023
13.37M
Average
11.14M
Median
Revenue (Quarterly) Benchmarks
| Accuray Inc | 101.54M |
| Aethlon Medical Inc | -- |
| AIM ImmunoTech Inc | 0.035M |
| Perspective Therapeutics Inc | -- |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 3.236M |
| Total Expenses (Quarterly) | 13.97M |
| EPS Diluted (Quarterly) | 0.03 |
| Enterprise Value | 94.82M |
| Gross Profit Margin (Quarterly) | 53.37% |
| Profit Margin (Quarterly) | 18.02% |
| Earnings Yield | -9.64% |
| Normalized Earnings Yield | -9.639 |